Tevogen Bio’s (TVGN) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Tevogen Bio (NASDAQ:TVGN) in a report published on Tuesday,Benzinga reports. The firm currently has a $10.00 price target on the stock.

Tevogen Bio Price Performance

Shares of TVGN opened at $1.27 on Tuesday. The stock has a 50 day simple moving average of $1.13 and a 200-day simple moving average of $1.20. Tevogen Bio has a 1 year low of $0.26 and a 1 year high of $3.09.

Insider Buying and Selling at Tevogen Bio

In other news, CEO Ryan H. Saadi sold 1,438,206 shares of Tevogen Bio stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $1.23, for a total transaction of $1,768,993.38. Following the transaction, the chief executive officer now owns 116,814,453 shares in the company, valued at $143,681,777.19. The trade was a 1.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 73.24% of the company’s stock.

Institutional Investors Weigh In On Tevogen Bio

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. raised its holdings in shares of Tevogen Bio by 74.2% in the fourth quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company’s stock valued at $40,000 after purchasing an additional 16,695 shares during the last quarter. Barclays PLC grew its position in Tevogen Bio by 39.2% in the fourth quarter. Barclays PLC now owns 45,600 shares of the company’s stock valued at $48,000 after purchasing an additional 12,847 shares in the last quarter. XTX Topco Ltd acquired a new stake in Tevogen Bio in the 4th quarter valued at $55,000. Nuveen LLC acquired a new stake in Tevogen Bio in the 1st quarter valued at $97,000. Finally, Northern Trust Corp lifted its position in Tevogen Bio by 13.0% during the 4th quarter. Northern Trust Corp now owns 118,415 shares of the company’s stock worth $122,000 after buying an additional 13,595 shares in the last quarter.

Tevogen Bio Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.